Sanofi to Acquire Provention Bio for USD 2.9 Billion
Sanofi and Provention Bio, Inc., a publicly traded biopharmaceutical company based in the United States focused on intercepting and preventing immune-mediated diseases such as type 1 diabetes (T1D), have agreed to acquire Provention Bio, Inc. for $25.00 per share in cash, representing an equity value of approximately $2.9 billion.
The acquisition adds an innovative, fully owned, first-in-class therapy in type 1 diabetes to Sanofi's core asset portfolio in General Medicines, accelerating the company's strategic shift toward differentiated products. Last year, the FDA approved TZIELD (teplizumab-mzwv) as the fir...
